PPARG and urinary bladder neoplasm: Therefore, despite our promising findings show PPARγ agonists are more effective in combination therapy and particularly render bladder tumor sensitive to EGFR inhibition, a better understanding of the mechanism of activated PPARγ and EGFR inhibition is needed to evaluate the benefits from such therapy in future clinical applications.